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Abstract: Epigallocatechin-3-Gallate (EGCG) has been extensively studied for its protective effect
against cardiovascular disorders. This effect has been attributed to its action on multiple molecular
pathways and transmembrane proteins, including the cardiac Nav1.5 channels, which are inhibited in
a dose-dependent manner. However, the molecular mechanism underlying this effect remains to be
unveiled. To this aim, we have characterized the EGCG effect on Nav1.5 using electrophysiology and
molecular dynamics (MD) simulations. EGCG superfusion induced a dose-dependent inhibition of
Nav1.5 expressed in tsA201 cells, negatively shifted the steady-state inactivation curve, slowed the
inactivation kinetics, and delayed the recovery from fast inactivation. However, EGCG had no
effect on the voltage-dependence of activation and showed little use-dependent block on Nav1.5.
Finally, MD simulations suggested that EGCG does not preferentially stay in the center of the
bilayer, but that it spontaneously relocates to the membrane headgroup region. Moreover, no sign of
spontaneous crossing from one leaflet to the other was observed, indicating a relatively large free
energy barrier associated with EGCG transport across the membrane. These results indicate that
EGCG may exert its biophysical effect via access to its binding site through the cell membrane or via a
bilayer-mediated mechanism.
Keywords: EGCG; Nav1.5; cellular electrophysiology; molecular dynamics; ion channels
1. Introduction
Ion channels are pore-forming transmembrane proteins involved with the transport of ions
through cell membranes. Their activity is essential for the excitation-contraction coupling in cardiac
cells. In this sense, the voltage-gated sodium channels generate the rapid action potential upstroke of
cardiomyocytes and thereby play a crucial role in heart excitability and conduction.
Within the nine isoforms of voltage-gated sodium channels, Nav1.5 displays a preponderant
expression in cardiac cells [1]. This isoform is composed of intracellular N and C terminal tails and
four homologous domains (DI-DIV), each consists of six transmembrane segments (S1–S6). These
domains fold together with their S5-S6 segments to build a highly selective Na+ pore [2,3].
Nav1.5 dysfunction is linked with an increasingly wide range of inherited cardiac
arrhythmias [4,5]. Gain-of-function mutations of this channel are associated with many disorders such as
the congenital long QT syndrome, multifocal ectopic Purkinje-related premature contractions (MEPPC),
and exercise-induced polymorphic ventricular tachycardia [6–11]. Whereas the loss-of-function
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mutations are linked with Brugada syndrome, sick sinus syndrome, and cardiac conduction
disease [4,5,12]. In the same line, mutations in genes encoding proteins that regulate, directly
or indirectly, Nav1.5 function are associated with many cardiac arrhythmias [13]. This is true for many
Nav1.5-interacting proteins such as Nav-β subunits, Plakophillin-2, and more recently for the nuclear
proteins Lamin A/C [14–17]. As such, Nav1.5 channels become highly targeted by several drug classes,
including anti-arrhythmic drugs [18], despite their associated side effects [19].
In this context, bioactive molecules extracted from medicinal plants are pledged to offer added
values in preventing arrhythmic episodes. Epigallocatechin-3-Gallate (EGCG), the predominant
polyphenol of green tea, was shown to be a promising natural alternative in the setting of cardiac
arrhythmia [20,21].
Green tea extracts and EGCG have been extensively studied for their protective effects against
cardiovascular disorders. Many authors have shown that green tea consumption is associated
with a lower risk of heart disease and reduced cardiovascular mortality [22,23]. Moreover, several
experimental studies revealed that EGCG reduces chronic ventricular remodeling after myocardial
ischemia in rats [24], improves left ventricular dysfunction, suppresses myocardial inflammation in rat
autoimmune myocarditis [25], modulates arrhythmogenic activity, and calcium homeostasis of rabbit
left atrium [21], and inhibits angiotensin II-induced cardiomyocyte hypertrophy [26].
The cardiac activity of EGCG has been attributed to its effect on multiple intracellular molecular
pathways and transmembrane proteins [20–22,26–28], including Nav1.5. This compound has shown a
dose-dependent inhibitory effect on the cardiac sodium current INa [21,29,30]. However, the molecular
and biophysical mechanism underlying this effect remains to be unveiled. To this aim, we have worked
out to characterize the mechanisms underlying the EGCG effect on the cardiac sodium channel Nav1.5.
2. Results
2.1. Inhibitory Effect of EGCG on Human Nav1.5 Channels
The pharmacological effects of EGCG (Figure 1a) on the cardiac sodium channel isoform were
investigated using tsA201 cells transiently transfected with the human Nav1.5 channel in the presence of
its regulatory subunit Nav-β1. The latter is known for its effect on increasing the functional expression
of Nav1.5 channels in many heterologous systems [14]. INa currents were generated by 15 ms step
depolarization to −20 mV from a holding potential of −100 or −80 mV at a frequency of 0.33 Hz.
As previously reported by Kang et al. [30], EGCG superfusion induced a dose-dependent inhibition of
the Nav1.5 channel. The IC50 for the EGCG inhibition was 31.2 ± 3.6 µM when measured from the
−100 mV holding potential (Figure 1b–d) and 2.1 ± 1 µM when measured at −80 mV (Figure 1e,f). On
the other hand, EGCG dose-dependent effect on the fast inactivation kinetics was investigated. This
resulted in slowing the inactivation kinetics as long as the EGCG concentrations increased, mainly at
50 and 100 µM (Supplementary Figure S1).
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Figure 1. Pharmacological effects of Epigallocatechin-3-Gallate (EGCG) on the cardiac sodium 
channel Nav1.5. (a) Chemical structure of EGCG. (b) Time course recording of the INa current in the 
presence of various concentrations of EGCG. The dashed line represents the zero current. (c) 
Representative traces of INa currents in the presence of various EGCG concentrations at holding 
potential −100 mV. (d) Dose-response effects of EGCG on the inhibition of INa peak currents (holding 
potential = −100 mV, IC50 = 31.2 ± 3.6 µM, n = 8). (e) Representative traces of INa currents in the presence 
of various EGCG concentrations at holding potential −80 mV. (f) Dose-response effects of EGCG on 
the inhibition of INa peak currents (holding potential = −80 mV, IC50 = 2,1 ± 1 µM, n = 5–7). 
  
Figure 1. Pharmacol gical effects of Epigallocatechin-3-Gallate (EGCG) on the cardiac sodium channel
Nav1.5. (a) Chemical structure of EGCG. (b) Time course recording of the INa current in the presence
of various concentrations of EGCG. The dashed line represents the zero current. (c) Representative
traces of INa currents in the presence of various EGCG concentrations at holding potential −100 mV.
(d) Dose-response effects of EGCG on the inhibition of INa peak currents (holding potential = −100 mV,
IC50 = 31.2 ± 3.6 µM, n = 8). (e) Representative traces of INa currents in the presence of various EGCG
concentrations at holding potential −80 mV. (f) Dose-response effects of EGCG on the inhibition of INa
peak currents (holding potential = −80 mV, IC50 = 2,1 ± 1 µM, n = 5–7).
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2.2. Effect of EGCG on the Voltage-Dependence Properties of Nav1.5 Channels
The second step of EGCG pharmacological characterization was to study the compound effect
on Nav1.5 biophysics. For this aim, the voltage-dependence properties of Nav1.5 channels were
investigated in the presence or absence of 30 µM EGCG. The superfusion of this compound inhibited
the cardiac sodium channels (Figure 2a,b, Table 1), induced a shift of steady-state inactivation towards
more negative potentials (Figure 2c, Table 1), slowed the inactivation kinetics (Figure 3a,c, Table 1),
and delayed the recovery from fast inactivation (Figure 3d, Table 1). Moreover, EGCG did not modify
the voltage-dependence of activation but significantly affected the activation curve slope (Figure 2d,
Table 1).
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Figure 2. Effect of EGCG on the gating properties of Nav1.5 channels. (a) Representative traces of INa 
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Figure 2. Effect of EGCG on the gating properties of Nav1.5 channels. (a) Representative traces of INa
current in the presence or the absence of 30µM of EGCG. (b) I/V relationship in the presence or the absence
of EGCG. (c,d) Effect of EGCG on the voltage-dependence of inactivation and activation, respectively.
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Table 1. Effect of EGCG on the gating properties of Nav1.5 channels.
Control 30 µM EGCG
Peak current densities at −20 mV
(pA/pF) −146.2 ± 17.8; n = 12 −64.3 ± 7.3 ***; n = 12
V1/2 activation (mV) −27.4 ± 0.8; n = 12 −27.4 ± 1; n = 12
Activation slope (mV) 6.7 ± 0.2; n = 12 8 ± 2 ***; n = 12
Time to peak at −20 mV (ms) 1.12 ± 0.02; n = 12 1.16 ± 0.03; n = 12
V1/2 inactivation (mV) −79.4 ± 1.3; n = 13 −87 ± 0.9 ***; n = 13
Inactivation slope (mV) 5 ± 0.2; n = 13 5.5 ± 0.2 *; n = 13
t1/2 inactivation at −20 mV (ms) 0.43 ± 0.02; n = 12 0.56 ± 0.03 **; n = 12
Recovery from fast inactivation (ms)
τfast,1 5.1 ± 0.9; n = 5 24.3 ± 7.1 *; n = 5
τfast,2 110 ± 28.6; n = 5 233.7 ± 37.6 *; n = 5
* p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 3. Effect of EGCG on INa kinetics. (a) Representative traces of normalized INa current in the 
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Figure 3. Effect of EGCG on INa kinetics. (a) Representative traces of normalized INa current in the
presence or the absence of 30 µM of EGCG. INa currents were normalized to the maximal peak current
measured, in each condition, at −20 mV. EGCG effect on INa time to peak (b), inactivation kinetics (c),
and recovery from fast inactivation (d; inset, zoom on the interval between 0 and 300 ms).
2.3. EGCG did not Produce any Use-Dependent Blockade of Nav1.5 Channels
To characterize the potential use-dependent block (UDB) of EGCG on INa current, the effect of
rapid pulsing on Nav1.5 was investigated via the application of a series of 50 15 ms depolarizing
pulses from −100 to −20 mV at various stimulation rates (1 and 10 Hz). After the establishment of the
whole-cell configuration, cells were allowed to stabilize before the first run of the UDB protocol in the
Molecules 2020, 25, 902 6 of 14
absence of EGCG. Then, EGCG was perfused for 3 min while the membrane potential was held at
−100 mV, followed by the UDB protocol under 30 µM EGCG.
After the application of EGCG, INa currents were slightly but significantly reduced by 7% and 8%
compared with the control when pulsing at 1 and 10 Hz, respectively (Figure 4a,b, Table 2). These
results suggest that there is little or no use-dependent blockade of EGCG on Nav1.5 related currents.
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Figure 4. Use-dependent block protocol in the presence or absence of 30 µM EGCG. (a) Representative 
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Table 2. Characterization of the use-dependent block of EGCG. 
 UDB-1 Hz UDB-10 Hz 
Figure 4. Use-dependent block prot c l in the presence or absence of 30 µM EGCG. (a) Representative
trace of INa currents at 1 and 10 Hz in the presence of 30 µM of EGCG. (b) Normalized INa current
versus pulse number in the presence or absence of 30 µM of EGCG at 1 and 10 Hz. (c) Representative
trace of INa currents at 1 and 10 Hz in the presence of 100 µM of Mexiletine. (d) Normalized INa current
versus pulse number in the presence or absence of 100 µM of mexiletine at 1 and 10 Hz.
Table 2. Characterization of the use-dependent block of EGCG.
UDB-1 Hz UDB-10 Hz
EGCG (30 µM) 0.93 ± 0.01 **, n = 5 0.90 ± 0.02 *, n = 5
Mexiletine (100 µM) 0.86 ± 0.01 ***, n = 4 0.21 ± 0.04 ***, n = 4
* p < 0.05, ** p < 0.01, *** p < 0.001 versus control.
To validate our experimental conditions, especially the used UDB protocol, mexiletine has been
used as a positive control. As shown in Figure 4c,d, the application of 100 µM mexiletine significantly
reduces the INa current by 17% and 77% compared with the control when pulsing at 1 and 10 Hz,
respectively. These findings demonstrated the ability of the applied UDB protocol to characterize the
use-dependent block of a given drug.
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2.4. MD Simulations Suggest that EGCG does not Spontaneously Permeate Cell Membranes
To obtain a first insight into the mechanism through which EGCG may exert its effect on Nav1.5, the
interaction between EGCG and a model lipid membrane that mimics the environment in which Nav1.5
is found, was characterized. To this effect, molecular dynamics (MD) simulations of a system containing
EGCG initially positioned at the center of a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
bilayer, were carried out. Molecular dynamics simulations enable us to investigate the time-dependent
dynamical and structural properties of systems at the atomistic level. Three 1 µs simulations
suggested that EGCG did not preferentially stay in the center of the bilayer, but that it spontaneously
and consistently relocated to the membrane headgroup region (Figure 5). Over the course of the
simulations, no signs of spontaneous crossing from one leaflet to the other were observed, indicative of
a relatively large free energy barrier associated with EGCG transport across the membrane, that is not
easily crossed on the microsecond timescale. This finding is consistent with the molecule’s amphiphilic
nature. These results indicate that EGCG may not spontaneously permeate the membrane and become
able to block the Nav1.5 channel via the entrance to the internal cavity via the inner pore mouth.
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Figure 5. Molecular dynamics simulations show the preferential localization f in the headgroup
region of a POPC membrane. (a) Localization of EGCG molecules along 1-microsecond simulation
runs with respect to the bilayer center (0 nm). (b) Representative snapshot highlighting the preferential
localization of the EGCG in the headgroup region of a POPC bilayer (phosphate and nitrogen atoms
are shown as blue and brown spheres, respectively, the solution is shown as a grey surface and lipid
tails are omitted for clarity. The EGCG molecule is shown as cyan, red, and white spheres).
3. Discussion
The present study aimed to characterize the biophysical mechanism underlying the EGCG effect
on the cardiac sodiu channel Nav1.5.
Our results showed that EGCG inhibited the INa current in a concentration-dependent manner
either at a holding potential of −100 or at −80 mV. The IC50 of EGCG was much lower at a holding
potential of −80 mV compared to −100 mV, (IC50 = 32.4 ± 3.6 µM and 2.1 ± 1 µM at −100 mV and −80
mV, respectively). This demonstrates that the membrane holding potential affects the affinity of EGCG
to Nav1.5, suggesting that EGCG interacts with a higher affinity to the inactivated state of the cardiac
sodium channel. Similar results have been reported by Kang et al., showing a dose and state-dependent
inhibition of INa current in the presence of EGCG [30]. However, the obtained IC50 were different from
those published by these authors (100 µM and 24.6 µM at holding potentials of −90 mV and −70 mV,
respectively [30]). These discrepancies are likely related to different experimental conditions used
in the two studies. Kang et al., have stably transfected Nav1.5 in HEK293 cells in the absence of its
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regulatory subunit Nav-β1, investigated the pharmacological effect of ECGC at 35 ◦C, and used −90
or −70 mV as holding potentials to generate INa currents. In contrast to these conditions, we have
transiently transfected tsA-201 cells with Nav1.5 in the presence of Nav-β1, recorded INa currents
at room temperature (23–25 ◦C), and used −100 or −80 mV as holding potentials to generate INa
currents. These protocol changes may induce noticeable differences. Indeed, since Nav-βs are strong
modulators of Nav1.5 electrophysiological properties [14], the sensitivity of the cardiac sodium channel
towards EGCG may be affected by the presence or absence of Nav-β1. Furthermore, conducting
experiments at elevated temperatures may induce the degradation of EGCG and its epimerization
to gallocatechin-3-gallate (GCG) [31], which could trigger different biophysical modifications of INa
current as it was shown in rat dorsal root ganglion neurons [32]. On the other hand, under the same
conditions, the activity of EGCG on Nav1.5 could be altered as it was described for other INa inhibitors
such as flecainide, ajmaline, and ranolazine [33,34].
The biophysical mechanism of Nav1.5 inhibition by EGCG was further investigated by
characterizing the biophysical gating properties of these channels in the presence of 30 µM EGCG.
Under these conditions, EGCG shifts the voltage-dependence of inactivation curve toward more
negative potentials by 7.6 mV, slows the inactivation kinetics, and delays the recovery from fast
inactivation, indicating that EGCG binds to the inactivated state of Nav1.5. However, EGCG had no
effect on the voltage-dependence of activation and significantly affected the activation curve slope.
The modification of the activation slope may be caused by a more efficient clamp of the membrane
potential in the presence of 30 µM EGCG. Indeed, even with optimal compensation for series resistance
(Rs), the remaining uncompensated Rs combined with large and rapid INa currents let a voltage error
that could produce a loss of the voltage clamp. Thus, a reduced sodium current magnitude, as it has
been noticed in the presence of EGCG, could decrease the resulting series resistance error and improve
the voltage clamp quality.
On the other hand, the observed shift of the steady-state of inactivation is consistent with what
has been previously described for Nav1.5 [30]. One should note that the EGCG effects on the other
biophysical properties were mainly investigated on the neuronal Nav channels [32,35,36]. These
published results are in concordance with the EGCG effect on the fast inactivation kinetics, and recovery
from inactivation of the cardiac sodium channels.
With regards to the activation process, Kim et al. observed that 1µM EGCG did not affect the
voltage-dependence of activation of tetrodotoxin-sensitive and resistant INa currents in rat dorsal
root ganglion neurons [36], which was consistent with the results of the present study studying the
cardiac sodium current. In contrast, Deng et al. showed a negative shift of the activation curve in
the presence of EGCG in primary cultures of rat hippocampal neurons [35]. From our perspective,
these discrepancies could be related to the quality of the membrane potential clamp. Indeed, based on
the sodium current traces presented in Deng’s study, a sub-optimal voltage-clamp quality of these
currents is observed, which makes any interpretation difficult [35].
Furthermore, our investigations suggested that there is little or no use-dependent block of EGCG
on Nav1.5. The absence of the UDB could be explained by the slight modification of the recovery
from fast inactivation. Indeed, in the presence of EGCG, the almost “normal” recovery from fast
inactivation prevents an additional progressive accumulation of inactivated Nav1.5, which represents
the preferential binding state of EGCG. These findings are consistent with those obtained in other
studies testing the effect of gallocatechin-3-gallate on the tetrodotoxin-resistant voltage-gated sodium
channels in rat dorsal root ganglion neurons [32].
In a first attempt to characterize the molecular mechanism through which EGCG may exert its
effect on Nav1.5, we investigated how EGCG interacts with the lipidic environment surrounding
Nav1.5. Indeed, relatively hydrophobic compounds such as EGCG have been hypothesized to act on
membrane proteins either via direct interaction, via the effect on the membrane, or both. Voltage-gated
sodium channels, in particular, have fenestrations lining their pore domain, which enable modulators
to access the pore via the membrane. We thus sought to gain a first insight into how Nav channels
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may be modulated by EGCG by characterizing where this compound localized preferentially in a
membrane. This was done by carrying out MD simulations, which provided a detailed atomistic
view of the behavior of EGCG when it was placed in a model lipidic membrane: Calculations were
initiated with EGCG located at the center of the POPC bilayer. The obtained results suggest that EGCG
is spontaneously relocated to the membrane headgroup region.
The predicted re-localization of EGCG to the membrane head group is consistent with the results
of Salazar et al., which have demonstrated that EGCG modifies the activity of a membrane-bound
protein upon binding to the phospholipid head groups of the red blood cell membranes [37].
Similarly, Ingólfsson et al. have shown that the biological effects of green tea catechins could be
attributed to multiple molecular interactions because the catechins accumulate at the bilayer/solution
interface and modify bilayer properties that can influence gramicidin channel function [38]. However,
MD simulations results cannot exclude the possibility that EGCG exerts its biophysical effect via
access to its binding site, on Nav1.5, through the cell membrane. Indeed, as shown for local
anesthetics and antiarrhythmic drugs [39], the EGCG blocking effect could also be controlled by the
channel’s fenestrations.
The current findings support the hypothesis that EGCG could be used as an anti-arrhythmic
drug in the setting of Nav1.5 gain-of-function mutations; as has been suggested by Boukhabza et
al. These authors have predicted that EGCG may limit the cardiac cells hyperexcitability related to
the presence of Nav1.5-R222Q and Nav1.5-I141V mutants [20]. On the other hand, the present study
demonstrated that the membrane holding potential affects the affinity of EGCG to Nav1.5, suggesting
that EGCG interacts with a higher affinity to the inactivated state of the cardiac sodium channel.
Thus, we could expect an atrial-selective block of Nav1.5 channels due to a more depolarized resting
membrane potential in the atria compared to the ventricles. Then, a higher beneficial effect of EGCG
could be observed in the setting of atrial hyperexcitability phenotypes.
Nonetheless, it remains somehow challenging to interpret the clinical relevance of our results
even in the context of cardiac hyperexcitability phenotypes. Many in vitro studies have shown that
the effective concentrations of EGCG to target relevant pathophysiological pathways are typically
ranged from 1 to 1000 µmol/L. However, the pharmacological disposition of EGCG in humans
indicates that its serum concentration is in the nanomolar scale [40–48]. In addition, EGCG is well
known for its chemical instability under physiological conditions due to its easy degradation and
metabolism [31,49,50]. Therefore, any potential impact of EGCG intake may reflect the combined
effects of EGCG and its metabolites.
In conclusion, the present study suggests that EGCG may modulate the biophysical properties of
Nav1.5 via access to its binding site through the cell membrane or via a bilayer-mediated mechanism.
These results constitute a first step towards the characterization of the biophysical mechanism
underlying the inhibitory action of EGCG on Nav1.5. However, the exact molecular interactions
underlying these effects are still unknown and remain to be studied.
4. Materials and Methods
4.1. Cell Culture and Transfection
TsA-201 cells were cultured at 37 ◦C in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% Fetal Bovine Serum (FBS), 4 mM glutamine, and a cocktail of streptomycin-penicillin antibiotics
in a humidified atmosphere of 5% CO2 and 95% air. All cell medium components, except glutamine
(Sigma-Aldrich), were purchased from Gibco (Fisher Scientific, Zurich, Switzerland).
For electrophysiological experiments, tsA-201 cells were transiently transfected with DNA
complexed to JetPEI (Polyplus-transfection) according to the manufacturer’s instructions. DNA
concentrations were 1 µg of pCDN3.1-Nav1.5 and 1 µg of pIRES-hβ1-CD8. The resulting Nav1.5
protein was a splice variant lacking glutamine at position 1077 (Q1077del). Eight hours after transfection,
the cells were isolated and seeded in plastic Petri dishes at low density.
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4.2. Cellular Electrophysiology
Twenty-four hours after transfection, the resulting sodium current (INa) was recorded at room
temperature (23–25 ◦C), under whole-cell voltage-clamp conditions with Axon PClamp 10 software
through an A/D converter (Digidata 1440A) using an Axopatch 200B (all Axon Instruments Molecular
Devices Corp., CA, USA). Series resistances were compensated (up to 90% compensation), and the
residual capacitive currents were canceled using a P/4 protocol. The cells were bathed with an
extracellular solution containing (in mmol/L): NaCl 50, NMDG-Cl 80, CsCl 5, MgCl2 1.2, CaCl2 2,
HEPES 10, glucose 5. The pH was adjusted to 7.4 with CsOH. Glass pipettes (tip resistance: 1.5 to 3
MΩ) were filled with an intracellular medium containing (in mmol/L): Na2ATP 5, CsAsp 70, CsCl 60,
EGTA 11, CaCl2 1, MgCl2 1, HEPES 10. pH was adjusted to 7.2 with CsOH.
Activation properties of Nav1.5 channels were determined from I/V relationships by normalizing
the sodium current peak to the driving force. Steady-state inactivation was measured with a standard
double-pulse protocol. Cells were held at −100 mV before the application of 500 ms conditioning
pulses, ranging from −130 to −20 mV. Then, a 20 ms test pulse to −20 mV was applied. The measured
current was then normalized to the maximum peak current recorded after conditioning pulses (I/Imax)
and plotted as a function of conditioning step voltage. Activation and inactivation curves were fit to a
Boltzmann equation.
For the pharmacological investigation, the peak current amplitudes at different EGCG
concentrations were subtracted from the current obtained with the control solution and were normalized
to the control value:
Inhibition Percentage (%) = [(Icontrol − IEGCG)/Icontrol] × 100
IC50 was calculated according to Quest GraphTM IC50 Calculator (Quest GraphTM IC50 Calculator).
AAT Bioquest, Inc., 24 Apr. 2019, https://www.aatbio.com/tools/ic50-calculator).
4.3. Chemicals
Epigallocatechin-3-Gallate (EGCG, Sigma-Aldrich, CAS Number 989-51-5) was dissolved directly
into the external solutions. Fresh EGCG solutions were prepared before each experiment. During
the same day, EGCG solutions were renewed every 5 h to avoid compound degradation (e.g., brown
discoloration of solutions).
4.4. Molecular Dynamics Simulations
The 3D structure of the EGCG molecule was obtained from PubChem Database
((−)-Epigallocatechin gallate, CID = 65064). The system containing an EGCG molecule placed
at the center of a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine membrane and plunged in a 0.1 M
NaCl solution was prepared using the CHARMM-GUI server [51–53]. The lipid and ions interactions
were described using the CHARMM36 (Chemistry at Harvard Macromolecular Mechanics) force
field [54], whereas water molecules were modeled using the TIP3P model [55]. Simulations were
performed using the NPT ensemble, where the temperature and the pressure were maintained at
310 K and 1 atm, respectively, using Parinello–Rahaman pressure coupling [56] and Nose-Hoover
temperature coupling [57]. The cut-off value used to compute non-bonded interactions was set to 12 Å
and long-range electrostatic interactions were computed using the particle mesh Ewald method [58].
Three replicas 1 µs simulations were run using the GROMACS package version 2018.4 on our local
high-performance computing cluster [59]. Distances between the COM (Center of Mass) of EGCG
and the membrane were calculated by using the gmx distance analysis tool of GROMACS. EGCG was
parameterized using the SWISS-PARAM software [60].
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4.5. Data Analysis and Statistical Methods
Currents were analyzed with Clampfit software (Axon Instruments, San Jose, CA, USA). Data
were analyzed using a combination of pClamp10, Excel (Microsoft), Igor Pro (WaveMetrics), and Prism
(graphpad).
Comparisons between groups were performed with a two-tailed paired Student’s t-test. Data
were expressed as mean ± SEM. A p-value < 0.05 was considered significant.
5. Conclusions
In the current study, we have characterized the effect of epigallocatechin-3-gallate on the
cardiac sodium channel. This compound shows a higher affinity for the inactivated state of Nav1.5
without any effect on its activation process. In addition, molecular dynamics simulations have
predicted the re-localization of EGCG to the membrane headgroup region, suggesting that EGCG
may not spontaneously permeate the cell membrane and may exert it effects on Nav1.5 by a bilayer
mediated mechanism.
Supplementary Materials: The following are available online, Figure S1: EGCG dose-dependent effect on the
fast inactivation kinetics. (a) Representative traces of normalized INa current in the presence of various EGCG
concentrations. (b) EGCG effect on INa inactivation kinetics.
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